Organisation paid for research Program year 2024 Source: CMS Open Payments

Baltimore Early Phase Clinical Unit

Neither a doctor nor a teaching hospital

Research payments

$1,813,061

8 payments

Through program year 2024, Baltimore Early Phase Clinical Unit is reported as receiving $1,813,061 in research payments, across 8 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2024	Research	$30,462	2
2023	Research	$950,939	2
2022	Research	$820,230	3
2021	Research	$11,430	1

Breakdown

Who paid Research payments · program years 2021–2024

Vertex Pharmaceuticals Incorporated $1,813,061 8 payments

Studies the money was for Research payments · program years 2021–2024

A Phase 1, Open-label Study to Evaluate Pharmacokinetic Drug-drug Interactions Between VX-548 and Midazolam and Digoxin in Healthy Subjects $1,393,984 3 payments
A Phase 1, Open-label, Randomized, Crossover Study to Evaluate the Relative Bioavailability of a Test Formulation of VX-147 Compared to a Reference Tablet of VX-147 in Healthy Adult Subjects $407,426 2 payments
A Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy $11,651 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.